Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577016 | PMC |
| http://dx.doi.org/10.1038/s41431-024-01571-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deciphering the enigmatic PilY1 of : An analysis.
Biochem Biophys Rep
September 2024
Geomicrobiología, Metalurgia, UASLP, Sierra Leona 550, San Luis Potosí, 78210, SLP, Mexico.
Thirty years since the first report on the PilY1 protein in bacteria, only the C-terminal domain has been crystallized; there is no study in which the N-terminal domain, let alone the complete protein, has been crystallized. In our laboratory, we are interested in characterizing the Type IV Pili (T4P) of . We performed an characterization of PilY1 and other pilins of the T4P of this acidophilic bacterium.
View Article and Find Full Text PDF[Intrathecal baclofen therapy: a 30-year experience].
Zh Vopr Neirokhir Im N N Burdenko
June 2024
Ulyanov Chuvash State University, Cheboksary, Russia.
Background: The first pump for intrathecal administration of baclofen was implanted in 1984. Over thirty years, intrathecal prolonged infusion of muscle relaxants has occupied a worthy niche among all methods for correction of non-focal drug-resistant disabling muscle spasticity. However, this method has not become routine despite high awareness of specialists in Russia and abroad, as well as undeniable advantages for restoring the daily activity, improving the walking pattern and providing care and quality of life in people with limited mobility.
View Article and Find Full Text PDFPaclitaxel - a Product of Fungal Secondary Metabolism or an Artefact?
Planta Med
August 2024
German Research Ombudsman, Head of Office, Berlin, Germany.
Taxol (common name: paclitaxel) is an extremely important component of drugs for the treatment of various cancers. Thirty years after the discovery of its effectiveness, a metabolic precursor of Taxol (10-deacetylbaccatin III) is still primarily extracted from needles of European yew trees. In order to meet the considerable demand, hopes were pinned on the possibilities of biotechnological production from the very beginning.
View Article and Find Full Text PDFCRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment.
CNS Neurol Disord Drug Targets
October 2024
Department of Pharm Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune Maharashtra 411038, India.
In defiance of the vast amount of information regarding Alzheimer's disease (AD) that has been learned over the past thirty years, progress toward developing an effective therapy has been difficult. A neurological ailment that progresses and cannot be reversed is Alzheimer's disease, which shows neurofibrillary tangles, beta-amyloid plaque, and a lack of cognitive processes that is created by tau protein clumps with hyperphosphorylation that finally advances to neuronal damage without a recognized treatment, which has stimulated research into new therapeutic strategies. The protein CAS9 is linked to CRISPR, which is a clustered Regularly Interspaced Short Palindromic Repeat that inactivates or corrects a gene by recognizing a gene sequence that produces a doublestranded break has enchanted a whole amount of interest towards its potency to cure gene sequences in AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!